AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00160966
Drug: Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to Everolimus
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: according to Giessen protocol
Trial: NCT02273518
Drug: Asasantin ER, new formulation I
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02273518
Drug: Asasantin ER, new formulation II
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04393805
Drug: Low Molecular Weight Heparin
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thromboprophylaxis with Low Molecular Weight Heparin, mostly enoxaparin
Trial: NCT02273518
Drug: Asasantin ER, present commercial formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05274139
Drug: HD-MTX-Ara-C regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HD-MTX-Ara-C regimen high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine~1g/m2 bid d2-3.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles
Trial: NCT05274139
Drug: FTD regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTD regimen(fotemustine, temozolomide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt,temozolomide 150mg/m2 d1-5 po,dexamethasone 40mg d1-5 ivgtt.Continued use to the end of chemotherapy .Every 28 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles
Trial: NCT00649415
Drug: piroxicam
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: piroxicam 40 mg capsule QD for up to the first 3 days of the menstrual cycle
Trial: NCT00649415
Drug: valdecoxib
RxNorm normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: valdecoxib 40 mg capsule twice a day (BID), taken as required, on the first day of treatment in the menstrual cycle followed by oral valdecoxib 40 mg once a day (QD) for up to the first 3 days of the menstural cycle
Trial: NCT03392961
Drug: IN-105 (Insulin Tregopil)
RxNorm normalized name: POLOXAMER 105
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg strength tablets for oral use used at a dose of 30 mg
Trial: NCT01620489
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered once daily subcutaneously (s.c., under the skin) as add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen.
Trial: NCT05881109
Drug: Caspogunfin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No specific interventions were administrated. Participants receive interventions as part of routine medical care, where CAS was infused intravenously over 60 min at a loading dose of 70 mg/m2 on day 1, followed by a maintenance dose of 50 mg/m2 (maximum: 70 mg daily).
Trial: NCT03705884
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral course of Prednisolone for treatment of sarcoidosis (patient cohort) or as control (healthy volunteer cohort)
Trial: NCT01938300
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03210259
Drug: Humira®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration - 58 weeks
Trial: NCT02110706
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo group will receive a vehicle control infusion
Trial: NCT04322214
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily lactose capsules (as aspect cobicistat capsules)
Trial: NCT04223232
Drug: [14C]-MD1003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose of 100mg \[14C\]-MD1003
Trial: NCT02961218
Drug: ACZ885
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly doses of 4 mg/kg for subjects weighing ≤40 kg and 300 mg for all other subjects
Trial: NCT02961218
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly doses of placebo to match the administered dose of canakinumab s.c.
Trial: NCT04797715
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets, taken twice daily
Trial: NCT04256993
Drug: Other standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel, cabazitaxel, enzalutamide, abiraterone and others standard of care following the physician's prescription in routine clinical practice.
Trial: NCT04094298
Drug: FX006 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One injection of extended release triamcinolone. 32 milligram injection of the extended release triamcinolone in a 75:25 ratio of polylactic-co-glycolic acid (PLGA) microspheres to drug load of 25%. The drug product is reconstituted with diluent containing an isotonic, sterile aqueous solution of sodium chloride, carboxymethylcellulose sodium and polysorbate-80 to form a suspension prior to injection.
Trial: NCT00606827
Drug: Isotonic Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients assigned to the isotonic saline group received 1 ml/kg/h 0.9% sodium chloride for 12 hours before and after the procedure
Trial: NCT03534297
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hard opaque capsules containing 0 mg of API.
Trial: NCT02532777
Drug: Cyclophosphamide(CTX)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00686179
Drug: AZD3480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, oral, single dose, 6 days
Trial: NCT00686179
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, oral, single dose
Trial: NCT02532777
Drug: Angiotensin-converting enzyme inhibitor(ACEI)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00586846
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75mg/m\^2
Trial: NCT00586846
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate 12g/m\^2
Trial: NCT02049320
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00377000
Drug: clindamycin 1% / benzoyl peroxide 5% gel pump
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00377000
Drug: clindamycin 1% / benzoyl peroxide 5% tube
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02495012
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Freeze-dried powder without snake venom will be dissovled in saline
Trial: NCT00875368
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug
Trial: NCT02958878
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03779360
Drug: Erythromycin 4% topical gel formulation:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 day pre-treatment with erythromycin and clindamycin applied twice daily on marked area on left (erythromycin) and right side (clindamycin) of the volar lower arm. Erythromycin is a bacteriostatic antibiotic that belongs to the macrolide group of antibiotics. Macrolides act as bacteriostatic by reversibly binding to the P site on the 50S subunit of bacterial ribosomes. A topical gel formulation with hyprolose and ethanol.
Trial: NCT03779360
Drug: Clindamycin 1% lotion formulation:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 day pre-treatment with erythromycin and clindamycin applied twice daily on marked area on left (erythromycin) and right side (clindamycin) of the volar lower arm. Clindamcin is a bacteriostatic antibiotic that belongs to the lincosamide group of antibiotics. Lincosamides act as bacteriostatic by reversibly binding to the P site on the 50S subunit of bacterial ribosomes. A topical lotion formulation with ethanol.
Trial: NCT03779360
Drug: Prednisolone tablet (0.5mg/kg; parallel comparison):
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 day pre-treatment with prednisolone daily dose 0.5mg/kg (0.25mg/kg in the morning and 0.25mg/kg in the evening). Prednisolone tablet (0.5mg/kg; parallel comparison): Prednisolone is a synthetic corticosteroid with predominant glucocorticoid activity and as such it is widely used in the treatment for inflammatory and autoimmune diseases. Prednisolone exerts its effect by binding to cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators.
Trial: NCT02139306
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Placebo TID
Trial: NCT00029185
Drug: Dehydrex
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02140489
Drug: amosartan
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02140489
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02140489
Drug: amosartan and rosuvastatin
RxNorm normalized name: rosuvastatin and ezetimibe
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00400530
Drug: Comparator: Alendronate-Teva / Duration of Treatment: 1 Month
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01302379
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time
Trial: NCT02392130
Drug: LEO 130852A gel 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01735058
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound guided injection of 0.9% normal sodium hyaluronate line solution, at 2 mL/syringe, 3 weekly injections.
Trial: NCT01563432
Drug: Feburic®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg\*1 tablet
Trial: NCT01563432
Drug: TMX-67
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg\*2 tablets
Trial: NCT03792971
Drug: GC4419
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily 90 mg IV infusions over 60 minutes on Day 3 and Day 4
Trial: NCT00990561
Drug: Ultravate ointment twice daily + LacHydrin lotion twice daily
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical corticosteroid
Trial: NCT03971071
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once every 4 weeks. Subcutaneous injection.
Trial: NCT00990561
Drug: Ultravate ointment once daily + LacHydrin lotion twice daily
RxNorm normalized name: halobetasol Topical Lotion [Ultravate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroid
Trial: NCT00408876
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04147715
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet for oral administration
Trial: NCT03221907
Drug: GLA5PR GLARS-NF1 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet manufactured to mimic GLA5PR GLARS-NF1
Trial: NCT01344395
Drug: ropivacaine and ketorolac
RxNorm normalized name: phenylephrine and ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The RK-group receives four intra-articular injections via catheter with a total volume of 40 ml (380 mg ropivacaine and 60 mg ketorolac) combined with 4 intravenous injections of saline during 24 hours postoperatively
Trial: NCT01344395
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The K-group receives four intra-articular injections via catheter with a total volume of 40 ml saline combined with 4 intravenous injections of ketorolac (total 60 mg) during 24 hours postoperatively
Trial: NCT03819101
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg
Trial: NCT02445391
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT04492722
Drug: AZD5718
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive once daily oral dose of AZD5718 as per the arms they are randomised, and will continue until Week 20.
Trial: NCT01176344
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inert placebo capsules once monthly for 2 years.
Trial: NCT05419908
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Capsule
Trial: NCT04492722
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive once daily oral dose of placebo matched to AZD5718, and will continue until Week 20.
Trial: NCT01360632
Drug: Placebo + ADT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + FDA Approved Antidepressant (ADT)
Trial: NCT02867020
Drug: ADT
RxNorm normalized name: Radtue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing of goserelin (dose and frequency of administration) will be consistent with the prescribing information and should only be adjusted if clinically indicated to achieve and maintain subcastrate concentrations of testosterone (50 ng/dL or 1.7 nM).
Trial: NCT04021563
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascending single and multiple doses of placebo orally
Trial: NCT00141596
Drug: Cardura XL 4 mg bd
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00141596
Drug: Amiloride 5 mg bd
RxNorm normalized name: amiloride 5 MG
DrugBank: Amiloride (DB00594)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01352559
Drug: responders
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antidepressants administration for 6 weeks under therapeutic dose
Trial: NCT01352559
Drug: non-responders
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants administration for 6 weeks under therapeutic dose
Trial: NCT04181996
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patents will be randomized to receive either placebo or colchicine
Trial: NCT00864942
Drug: BLR-NHL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab 375 mg/m2 is given on day 1 on day 1 in addition to bendamustine 90 mg/m2 intravenously over 30-60 minutes on days 1 and 2 and lenalidomide orally daily every 28 days for a total of 6 cycles. After 6 cycles of bendamustine, lenalidomide and rituximab, lenalidomide monotherapy is administered as continued therapy for an additional 6 cycles as tolerated or until disease progression.
Trial: NCT01098240
Drug: CP-601,927
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-601,927 1-2 mg twice per day, oral 1 mg tablets, for 6 weeks.
Trial: NCT03501550
Drug: CDI-31244
FDA approved: no
EMA approved: no
PMDA approved: no
Description: investigational drug
Trial: NCT03501550
Drug: SOF/VEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sofosbuvir and velpatasvir fixed dose combination
Trial: NCT02653092
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02542384
Drug: CR845 IV 1 mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR845 IV 1 mcg/kg will be administered as an IV bolus 2x loading dose one hour prior to anesthetic induction for surgery, then a dose within 30 minutes of the patient being considered stable in the post operative recovery room. Subsequent dosing will be administered at 6, 12 and 18 hours.~Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed. Saline infusion (IV 0.45%) for fluid replenishment will be provided.
Trial: NCT00538564
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets taken orally 3 times a week for 2 months
Trial: NCT01956279
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 50mg BID x 14 days, followed by Placebo 150 x 14 days, followed by Placebo 250 mg BID x 28 days
Trial: NCT01416376
Drug: SRT2379
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRT2379 is supplied as hard gelatin capsules containing either 25mg or 250mg free-base equivalent of SRT23790 drug substance as its succinate salt.
Trial: NCT01416376
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the placebo capsules, the SRT2379 drug substance will be replaced by microcrystalline cellulose (Avicel PH200) to visually match the SRT2379 investigational product.
Trial: NCT00263276
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 0 mg, Once daily, 12 weeks.
Trial: NCT04237012
Drug: Dextenza 0.4Mg Intracanalicular Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: all patients will receive Intracanalicular dexamethasone, 0.4mg insert lower punctum and able to use over the counter artificial tears PRN at patient discretion
Trial: NCT02768740
Drug: Hydrocortisone hemisuccinate
RxNorm normalized name: Hydrocortisone Hemisuccinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the 200-mg group, patients received an intravenous bolus of 50 mg of hydrocortisone every six hours for seven days associated with a continuous infusion of placebo for five days. In the 300-mg group, patients received an initial bolus of 100 mg of hydrocortisone followed by a continuous infusion of 300 mg per day for five days associated with a bolus of placebo every six hours for seven days.
Trial: NCT01709578
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Trial: NCT01709578
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dispensed according to the local practice.
Trial: NCT00936884
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects received matching placebo injections.~Study duration: 2 weeks double-blind period (placebo treatments) followed by 12 weeks open-label extension period (MNTX treatments).
Trial: NCT04333771
Drug: SHR0302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo group will take drugs orally for 24 weeks, and then switch to SHR0302 dose1 for 28 weeks, in the meanwhile, SHR0302 dose1 group and SHR0302 dose2 group will continue taking drugs for the whole 52 weeks.
Trial: NCT04333771
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo group will take drugs orally for 24 weeks, and then switch to SHR0302 dose1 for 28 weeks, in the meanwhile, SHR0302 dose1 group and SHR0302 dose2 group will continue taking drugs for the whole 52 weeks.
Trial: NCT03096613
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine is used to normalize the thyroid hormone level of patients allocated to levothyroxine.
Trial: NCT02797964
Drug: SRA737
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRA737 will be administered orally on each day of a 28-day cycle. Subjects will receive a single dose of SRA737 between 4 to 7 days prior to starting the first cycle for PK profiling. Subjects can continue taking SRA737 if they are receiving clinical benefit and able to safely take the drug and follow the requirements of the study.
Trial: NCT01859390
Drug: AquADEKs-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AquADEKs-2 contains standard amounts of fat-soluble vitamins (A, D, E, K) that are contained in typical CF multivitamin supplements plus several antioxidants including beta-carotene, mixed tocopherols (different forms of vitamin E), coenzyme Q10 (CoQ10), mixed carotenoids (lutein, lycopene and zeaxanthin), and the minerals zinc and selenium.
Trial: NCT02209779
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01361399
Drug: Acetylsalicylic acid (Aspirin, BAYE4465) & Lidocain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral application of a fixed combination of Aspirin and Lidocain (as one lozenge)
Trial: NCT01361399
Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single oral application of Aspirin (as lozenge)
Trial: NCT01361399
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral application of Placebo (as lozenge)
Trial: NCT02269215
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03105115
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intrathecal fentanyl will be added as adjuvant for spinal anesthesia using heavy bupivacaine, while dexmedetomidine will be infused intravenously during operation
Trial: NCT01865084
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02469376
Drug: [18F]-GP1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiopharmaceutical Product (Tracer) to visualize with Positron Emission Tomography a thrombus in humans.
Trial: NCT03052764
Drug: Placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline) injection into the bladder.
Trial: NCT00004797
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03861611
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants may be randomized to receive Ketorolac oral medication 10 mg, every 8 hours for 5 days as needed